Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Phase 2

Completed

• Conditions: Pruritus; Psoriasis
• Interventions: Drug: 5 mg Serlopitant Tablets; Drug: Matching Placebo Tablets

• Registration Number: NCT03343639
• Lead Sponsor: Vyne Therapeutics Inc.

Brief Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with plaque psoriasis

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-01
• Study First Submitted: 2017-11-10
• Study First Submitted QC: 2017-11-10
• Study First Posted: 2017-11-17
• Primary Completion: 2018-10-23
• Study Completion: 2018-11-12
• Results First Submitted: 2019-05-23
• Results First Submitted QC: 2019-05-23
• Results First Posted: 2019-06-12
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-18
• Last Update Posted: 2021-05-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 204

Inclusion Criteria

1. Male or female, age 18-80 years at consent.

2. Diagnosis of plaque psoriasis for at least 6 months prior to randomization.

   a. Presence of plaque psoriasis in any anatomic location, covering ≤ 10% BSA in total, at the Screening and Baseline visits.

3. Pruritus of at least 4 weeks' duration prior to the initial Screening visit, and throughout the screening period prior to randomization.

4. Subjects must be willing to discontinue use of all psoriasis therapies other than the following, for the duration of the study: bland emollients (e.g., Cetaphil, Eucerin, Aquaphor) on any anatomic location; coal tar shampoos, limited to use on scalp.

5. WI-NRS initial screening score consistent with severe pruritus.

6. WI-NRS scores during the 2 weeks of screening consistent with sever pruritus.

7. All female subjects who are of childbearing potential must be willing to practice highly effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per year) from the time of the initial Screening visit until 2 weeks after last dose of study drug.

8. Weight ≥ 32 kg at the Screening and Baseline visits.

9. Willing and able to complete daily eDiary entries within a consistent timeframe for the duration of the study.

   1. Subjects must have ≥ 80% eDiary completion rate during the two weeks of the screening period immediately prior to randomization.

Read More

Exclusion Criteria

1. Prior treatment with serlopitant.

   a. Prior treatment with other neurokinin-1 receptor (NK1-R) antagonists (e.g., aprepitant, fosaprepitant, rolapitant) is not allowed within 1 year prior to randomization.

2. Clinical worsening of psoriasis in the opinion of the investigator (e.g., increase in affected BSA or severity requiring use of systemic psoriasis therapies) within 12 weeks prior to randomization.

3. Predominance of non-plaque forms of psoriasis (e.g., guttate, drug-induced, pustular, erythrodermic).

4. Presence of any concurrent medical condition that provides a clearly defined etiology for pruritus other than psoriasis. These include but are not limited to urticaria, atopic dermatitis or other dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, untreated hyperthyroidism, and infection.

5. Treatment with systemic biologic therapies including but not limited to etanercept, infliximab, adalimumab, ustekinumab, secukinumab, or ixekizumab, within 6 months or 5 half-lives (whichever is longer) prior to randomization.

6. Treatment with systemic non-biologic psoriasis therapies, including but not limited to systemic corticosteroids, phosphodiesterase-4 inhibitors, Janus kinase inhibitors, cyclosporine, methotrexate, retinoids, hydroxyurea, mycophenolate mofetil, thioguanine, sirolimus, azathioprine, or fumaric acid derivatives, within 12 weeks prior to randomization.

7. Treatment with any of the following therapies within 4 weeks prior to randomization:

   a. Any topical/local psoriasis therapies other than those permitted per inclusion #4, including but not limited to topical corticosteroids, vitamin D analogues, calcineurin inhibitors, phosphodiesterase-4 inhibitors, Janus kinase inhibitors, non-shampoo forms of coal tar, salicylates, retinoids, anthralin, or excimer laser.

   i. Non-systemic corticosteroids that do not involve skin application (e.g., inhaled, intranasal, or intra-articular corticosteroids) will be permitted.

   b. Phototherapy, with or without psoralen. c. Use of an indoor tanning facility, or sun exposure likely to result in sunburn.

   d. Systemic therapies with recognized anti-pruritic properties including but not limited to H1 antihistamines, doxepin, mirtazapine, gabapentin, pregabalin, cannabinoids, and kappa opioid receptor agonists.

   e. Any topical anti-pruritic therapies, including but not limited to H1 antihistamines, doxepin, capsaicin, or medicated emollients (e.g., menthol or pramoxine).

   f. Strong CYP3A4 inhibitors.

8. Treatment with any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to randomization.

9. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2x the upper limit of normal (ULN) during screening.

10. History of malignancy within 5 years prior to randomization, with the exception of completely treated and non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin.

11. Presence of any of the following conditions meeting DSM-5 diagnostic criteria within 3 years prior to randomization: major depressive disorder, bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use disorder, or other known psychiatric condition meeting DSM-5 diagnostic criteria which may confound the assessment of serlopitant safety or efficacy, compromise the safety of the subject, or interfere with the subject's ability to comply with protocol-mandated activities.

12. Suicidal ideation within 3 years prior to randomization, or history of suicide attempt at any time.

13. Known active hepatitis infection.

14. Known history of human immunodeficiency virus (HIV) infection.

15. Documented history of parasitic infection, including skin parasites such as scabies, within 12 months prior to randomization.

16. History of hypersensitivity to serlopitant or any of its components.

17. Currently pregnant or breastfeeding female subject.

18. Presence of any medical condition or disability that, in the investigator's opinion, could interfere with the assessment of serlopitant safety or efficacy, compromise the safety of the subject, or interfere with the subject's ability to comply with protocol-mandated activities; this includes any clinically significant screening ECG abnormalities any may include some clinically significant screening laboratory abnormalities.

    a. Unless specifically excluded per exclusion #9, clinically significant laboratory abnormalities at screening which are unlikely to interfere with the assessment of safety or efficacy in this trial, compromise the safety of the subject, or interfere with the subject's ability to comply with protocol mandated activities are permitted.

19. Planned or anticipated major surgical procedure or other activity that would interfere with the subject's ability to comply with protocol-mandated assessments (e.g., extended international travel) during the subject's participation in the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
5 mg Serlopitant Tablets	5 mg Serlopitant Tablets	Serlopitant Tablets
Matching Placebo Tablets	Matching Placebo Tablets	Placebo Tablets

Primary Outcome Measures

Name	Time	Method
WI-NRS 4-point Responder Rate at Week 8	8 weeks	Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. A 4-point responder is a subject who had at least a 4-point reduction in score between Baseline and Week 8.

Secondary Outcome Measures

Name	Time	Method
WI-NRS 4-point Responder Rate at Week 4	4 weeks	Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. A 4-point responder is a subject who had at least a 4-point reduction in score between Baseline and Week 4.
Change in WI-NRS From Baseline to Day 7	Change from baseline to day 7	Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. The secondary outcome is the change in WI-NRS score at 7 days compared with Baseline.
Change in WI-NRS From Baseline to Day 3	3 days	Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. The secondary outcome is the change in WI-NRS score at 3 days compared with Baseline.

Trial Locations

Locations (39)

Study Site 376; 🇺🇸 Santa Monica, California, United States

Study Site 213; 🇺🇸 Boise, Idaho, United States

Study Site 207; 🇺🇸 South Bend, Indiana, United States

Study Site 371; 🇺🇸 Saint Joseph, Missouri, United States

Study Site 356; 🇺🇸 San Diego, California, United States

Study Site 202; 🇺🇸 San Diego, California, United States

Study Site 215; 🇺🇸 San Diego, California, United States

Study Site 331; 🇺🇸 Miami, Florida, United States

Study Site 348; 🇺🇸 Miami, Florida, United States

Study Site 224; 🇺🇸 Houston, Texas, United States

Study Site 227; 🇺🇸 Omaha, Nebraska, United States

Study Site 221; 🇺🇸 Bryant, Arkansas, United States

Study Site 220; 🇺🇸 Beverly Hills, California, United States

Study Site 204; 🇺🇸 Fremont, California, United States

Study Site 212; 🇺🇸 Clearwater, Florida, United States

Study Site 210; 🇺🇸 Coral Gables, Florida, United States

Study Site 222; 🇺🇸 North Miami Beach, Florida, United States

Study Site 206; 🇺🇸 Sanford, Florida, United States

Study Site 360; 🇺🇸 New Albany, Indiana, United States

Study Site 228; 🇺🇸 Louisville, Kentucky, United States

Study Site 506; 🇺🇸 Ann Arbor, Michigan, United States

Study Site 216; 🇺🇸 Louisville, Kentucky, United States

Study Site 219; 🇺🇸 Clinton Township, Michigan, United States

Study Site 209; 🇺🇸 Fridley, Minnesota, United States

Study Site 375; 🇺🇸 Forest Hills, New York, United States

Study Site 201; 🇺🇸 East Windsor, New Jersey, United States

Study Site 516; 🇺🇸 Bexley, Ohio, United States

Study Site 500; 🇺🇸 New York, New York, United States

Study Site 211; 🇺🇸 Broomall, Pennsylvania, United States

Study Site 345; 🇺🇸 Johnston, Rhode Island, United States

Study Site 359; 🇺🇸 Pflugerville, Texas, United States

Study Site 205; 🇺🇸 Murfreesboro, Tennessee, United States

Study Site 182; 🇺🇸 College Station, Texas, United States

Study Site 339; 🇺🇸 Plano, Texas, United States

Study Site 203; 🇺🇸 San Antonio, Texas, United States

Study Site 223; 🇺🇸 Sugar Land, Texas, United States

Study Site 226; 🇺🇸 Webster, Texas, United States

Study Site 217; 🇺🇸 Norfolk, Virginia, United States

Study Site 336; 🇺🇸 Richmond, Virginia, United States